Boston Scientific Corp/ US1011371077 /
| 2024-08-28 9:59:59 PM | Chg. -0.32 | Volume | Bid9:59:59 PM | Ask9:59:59 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 79.52USD | -0.40% | 131,277 Turnover: 10.42 mill. |
79.49Bid Size: 500 | 79.52Ask Size: 200 | 117.1 bill.USD | - | 73.63 |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 1.08 USD | 140.00% |
| EPS Diluted: | 1.07 USD | 137.78% |
| Revenues per Share: | 9.71 USD | 9.81% |
| Book Value per Share: | 13.31 USD | 8.69% |
| Cash Flow per Share: | 1.71 USD | 60.41% |
| Dividend per Share: | - USD | - |
| Total | in mill. | |
| Revenues: | 14,240.00 USD | 12.29% |
| Net Income: | 1,570.00 USD | 144.55% |
| Operating Cash Flow: | 2,503.00 USD | - |
| Cash and Cash Equivalents: | 865.00 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 73.63 | 53.53 |
| P/S Ratio: | 8.19 | 5.96 |
| P/BV ratio: | 5.97 | 4.34 |
| P/CF Ratio: | 46.61 | 33.88 |
| PEG: | 0.53 | 0.38 |
| Earnings Yield: | 1.36% | 1.87% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 117.1 bill. USD | 84.81 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | 1.47 bill. | |
Profitability
| Gross Profit Margin: | 69.49% |
| EBIT Margin: | 16.45% |
| Net Profit Margin: | 11.03% |
| Return on Equity: | 8.04% |
| Return on Assets: | 4.47% |
Financial Strength
| Liquidity I / Cash Ratio: | 17.54% |
| Liquidity II / Quick Ratio: | 62.70% |
| Liquidity III / Current Ratio: | 132.05% |
| Debt / Equity Ratio: | 79.91% |
| Dynam. Debt / Equity Ratio: | 623.49% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | - USD |
| Net Income / Employee: | - USD |
| Total Assets / Employee: | - USD |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | US GAAP |
| Currency: | USD |
